卵巢癌市場:KOL的洞察

本報告提供全球卵巢癌市市場相關調查，提供市場概要，以及已通過核准治療方法，開發平台趨勢，未來預測等資訊。

目錄

摘要整理

現在及未來的治療流程

調查目的

已上市產品

• PARPis
  • PARPis(Lynparza，Rubraca，Zejula)相關洞察
  • LYNPARZA(oraparibu，AstraZeneca/Merck & Co.)
  • Rubraca(rukaparibu，Clovis Oncology)
  • zejura(niraparibu，GSK)
• ADC/管磷抑制劑
  • ADC/管磷抑制劑相關洞察
  • Elahere(mirubetsukishimabusorafutanShinn，ImmunoGen)

開發中產品

• 免疫查核點抑制劑(ICI)
  • ICI級相關洞察
  • babenshio(Avelumab，Merck Group)
  • imifinji(Durvalumab、 AstraZeneca)
  • jenperi(dosutarimabu，GSK)
  • KEYTRUDA(Pembrolizumab，Merck &Co.)
  • Opdivo/yaboi(Nivolumab/Ipilimumab，BMS/小野)
  • TECENTRIQ(Atezolizumab，Roche)
• 治療用疫苗
  • oregobomabu(抗個體遺傳型mAb，OncoQuest)
  • Olvi-Vec(olvimulogene nanivacirepvec，Genelux Corporation)
  • 裝載Vigil(Bi-shRNAfurin-GM-CSF的癌細胞疫苗，Gradalis)
• 其他的後期階段的治療方法
  • UpRi(upifitamaburirusodochin，Adimab/Mersana Therapeutics)
  • Batiraxcept(GAS6-AXL途徑抑制劑，Aravive)
• 糖皮質激素受體拮抗劑
  • Korlym(rirakoriranto，Corcept Therapeutics)
  • 腫瘤治療領域(TTF，Novocure)
• 中期及初期階段的模式
  • 下一代ADC以及其他的MOA
  • AZD 1775/MK 1775(adaboseruchibu，Merck & Co/AstraZeneca)
  • AZD 8205( AstraZeneca)
  • enherutsu(Trastuzumabderukusutekan、 AstraZeneca/第一三共)
  • IMGN 151(ImmunoGen)
  • MK-4830(Merck & Co)
  • REGN 4018(ubatamamabu，Regeneron)
  • SKB 264/MK-2870(Merck & Co)
  • STRO-002(ruberutamabutazebiburin，Sutro Biopharma)
  • VS-6766(automechinibu，Verastem Oncology)

附錄

Readouts of AstraZeneca's DUO-O positive study demonstrated significantly improved progression free survival - so why do KOLs doubt it will be practice changing? Experts are excited by the potential of ImmunoGen's ADC Elahere, but what safety concerns could impact its uptake? What factors underpin the prescribing of AstraZeneca/Merck & Co's Lynparza and GSK's Zejula PARP inhibitors? KOLs critically assess the prospects of launched and pipeline therapies.

Table of Contents

Executive summary (5)

Current and future treatment algorithm

Research objectives (2)

Marketed products (28)

• PARPis (14)
  • Insights for the PARPis (Lynparza, Rubraca, Zejula) (3)
  • Lynparza (olaparib; AstraZeneca/Merck & Co.) (1)
  • Rubraca (rucaparib; Clovis Oncology) (1)
  • Zejula (niraparib; GSK) (9)
• ADC/tubulin inhibitors (14)
  • Insights for the ADC/tubulin inhibitor (3)
  • Elahere (mirvetuximab soravtansine; ImmunoGen) (11)

Pipeline products (78)

• Immune checkpoint inhibitors (ICI) (15)
  • Insights for the ICI class (3)
  • Bavencio (avelumab; Merck Group) (1)
  • Imfinzi (durvalumab; AstraZeneca) (1)
  • Jemperli (dostarlimab; GSK) (1)
  • Keytruda (pembrolizumab; Merck & Co.) (1)
  • Opdivo/Yervoy (nivolumab/ipilimumab; BMS/Ono) (1)
  • Tecentriq (atezolizumab; Roche) (7)
• Therapeutic vaccines (22)
  • Oregovomab (anti-idiotype mAb; OncoQuest) (10)
  • Olvi-Vec (olvimulogene nanivacirepvec; Genelux Corporation) (6)
  • Vigil (Bi-shRNAfurin-GM-CSF-loaded tumour cell vaccine; Gradalis) (6)
• Other late-stage modalities (14)
  • UpRi (upifitamab rilsodotin; Adimab/Mersana Therapeutics) (7)
  • Batiraxcept (GAS6-AXL pathway inhibitor; Aravive) (7)
• Glucocorticoid receptor antagonists (11)
  • Korlym (relacorilant; Corcept Therapeutics) (7)
  • Tumour treating fields (TTFs; Novocure) (4)
• Mid and early-stage modalities (16)
  • Next-generation ADCs and other MOAs (2)
  • AZD 1775/MK 1775 (adavosertib; Merck & Co/AstraZeneca) (1)
  • AZD 8205 (AstraZeneca) (1)
  • Enhertu (trastuzumab deruxtecan; AstraZeneca/Daiichi Sankyo) (1)
  • IMGN 151 (ImmunoGen) (1)
  • MK-4830 (Merck & Co) (1)
  • REGN 4018 (ubamatamab; Regeneron) (1)
  • SKB 264/MK-2870 (Merck & Co) (1)
  • STRO-002 (luveltamab tazevibulin; Sutro Biopharma) (1)
  • VS-6766 (avutometinib; Verastem Oncology) (6)

Appendix (4)

• KOL details (4)
  • KOLs from the US (1)
  • KOLs from Europe (2)